Danish Pharmacovigilance Update, 26 September 2013

21 November 2013

In this issue of Danish Pharmacovigilance Update:

News from the EU

  • Filgrastim (Neupogen) and pegfilgrastim (Neulasta) are associated with risk of capillary leak syndrome
  • Use of bromocriptine (Parlodel®) for prevention or suppression of lactation is to be reassessed
  • Pregnancy prevention programme during treatment with Erivedge
  • Risk of hypermagnesaemia from the use of the parenteral nutrition preparations Numeta G13E and G16E
  • Be aware of the bleeding risk factors associated with the use of the new oral anticoagulants Eliquis®, Pradaxa® and Xarelto®
  • Lariam® and neuropsychiatric adverse reactions
  • Use of short-acting beta-agonists for obstetric indications

News from the Danish Health and Medicines Authority

  • Psychotic or manic symptoms emerging during use of methylphenidate and atomoxetine
  • Adverse reaction reports concerning the HPV vaccine from 1 January through 9 September 2013

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.